RAMOT at Tel Aviv University Ltd.

ZZ-PE38: a universal technology for immunotherapy

Posted by RAMOT at Tel Aviv University Ltd.Responsive · Innovative Products and Technologies · Israel

Summary of the technology

A novel fusion protein capable of binding to any internalizing IgG, thus forming a specific and potent immunotoxin, has been developed. The antibody-toxin conjugate is formed through an immuno-complex and may be further stabilized by chemical crosslinking. Such immunotoxins undergo efficient internalization, thus delivering the cytotoxic cargo and killing the target cells.
Project ID : 10-2009-83

The Technology
A novel fusion protein capable of binding to any internalizing IgG, thus forming a specific and potent immunotoxin, has been developed. The antibody-toxin conjugate is formed through an immuno-complex and may be further stabilized by chemical crosslinking. Such immunotoxins undergo efficient internalization, thus delivering the cytotoxic cargo and killing the target cells.

Immunotoxins are potent, targeted, cell-killing agents. They kill target cells via binding to a surface antigen, internalization and delivery of the cytotoxic cargo to the cell cytosol. Internalization is a pre-requisite for immunotoxin drug delivery approaches. To date, immunotoxins have not yet been proven as effective anti cancer agents. A few are undergoing clinical trials.

Potential Applications

  • Generating potent, site-specific antibody-toxin conjugates useful as anti cancer therapeutics.
  • Determining whether a particular antibody is suitable for anti-cancer therapy that requires internalization of the antibody-toxin conjugate.
  • Determining whether a particular cell-surface molecule is a potential immunotherapeutic drug target.

Advantages

  • Flexibility with regard to the targeting elements, as any of a variety of antibodies can be selected
  • Stable and less toxic
  • Simple, homogeneous, easy to construct

Data-to-date

  • anti-ErbB2-PE immunoconjugate was cytotoxic for human tumor cell lines expressing varying levels of ErbB2 receptors (breast adenocarcinoma SKBR3 epidermoid carcinoma A431, breast carcinoma T47D and MCF7, mammary carcinoma MDA-MB231).
  • IC50 values correlated with the levels of ErbB2 receptor expression.
  • SKBR3 and A431 tumor cells were most sensitive to the immunoconjugate with IC50 values of 3.5 ng/ml and 1.8 ng/ml, respectively.
  • Nude mice xenografts (s.c. human breast epidermoid carcinoma A431)
  • Mice treated at the 0.5 mg/kg dose level were in complete remission of the tumor that lasted for over one month until the animals were sacrificed.
  • anti-ErbB2 IgG-PE immunoconjugate had a serum half-life of 240 min.
  • Cetuximab ZZ-PE38 forms non-covalently bound complex. IC50 =0.00047 mg/ml
  • Treatment in vivo studies resulted in significantly smaller tumor size (SCC-1- H&N) (~70 mm3 to ~40 mm3 and ~20 mm3 )
  • Cetuximab-ZZ-PE38 complex was more effective than Cetuximab or ZZ-PE38 alone.
  • Cytotoxic effect of Cetuximab -ZZ PE38 complex is higher in cells expressing high EGFR
  • No cytotoxic effect of Cetuximab-ZZ-PE38 on normal fibroblast cells

Patent status

US 8,043,621 & CIP

Project manager

Adi Elkeles
BD Manager

Project researchers

Itai Benhar
T.A.U Tel Aviv University, Life Sciences
Molecular Microbiology-Biotechnology

Related keywords

  • Medicine, Human Health
  • Medical Technology / Biomedical Engineering
  • Virus, Virology / Antibiotics / Bacteriology
  • Biology / Biotechnology
  • Cellular and Molecular Biology Technology
  • Microbiology Technology
  • Bioinformatics Technology
  • Micro- and Nanotechnology related to Biological sciences
  • Monoclonal Antibodies and Hybridomas
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Bioinformatics Market
  • Therapeutic
  • Clinical Medicine
  • Pharmaceutical Indications
  • Life Sciences and Biotechnology
  • Antibodies
  • oncology
  • Life Sciences and Biotechnology
  • Drug delivery
  • oncology
  • Pharmaceutical Indications
  • Oncology / Cancer
  • oncology

About RAMOT at Tel Aviv University Ltd.

Technology Transfer Office from Israel

Ramot is Tel Aviv University's (TAU) technology transfer company and its liaison to industry, bringing promising scientific discoveries made at

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.